Multiple recent clinical trials highlight promise in advanced non-small cell lung cancer (NSCLC) therapy. Ionis Pharmaceuticals disclosed statistically significant Phase 3 results for olezarsen, demonstrating up to 72% triglyceride reduction and decreased acute pancreatitis risk in severe hypertriglyceridemia. Concurrently, the Phase 1 trial of DLL3-targeted ADC SHR-4849 produced encouraging outcomes in relapsed small cell lung cancer (SCLC). Additional studies reinforce combining osimertinib with chemotherapy or bispecific antibodies such as ivonescimab and iza-bren enhances progression-free and overall survival in EGFR-mutated NSCLC populations. However, geographic variability in ivonescimab efficacy could affect regulatory approvals in Western markets.